Needham & Company LLC Reiterates Buy Rating for Personalis (NASDAQ:PSNL)

Needham & Company LLC reaffirmed their buy rating on shares of Personalis (NASDAQ:PSNL - Free Report) in a research report report published on Wednesday morning,Benzinga reports. Needham & Company LLC currently has a $7.25 target price on the stock.

Separately, HC Wainwright reiterated a "buy" rating and set a $11.00 price target on shares of Personalis in a research report on Wednesday.

Personalis Trading Down 6.4 %

Shares of PSNL stock traded down $0.38 during trading on Wednesday, reaching $5.60. 1,703,489 shares of the company's stock traded hands, compared to its average volume of 1,113,378. The firm's 50-day moving average is $4.69 and its 200 day moving average is $4.32. The company has a market capitalization of $395.63 million, a P/E ratio of -3.33 and a beta of 1.75. Personalis has a 1 year low of $1.12 and a 1 year high of $7.20.

Personalis (NASDAQ:PSNL - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.31). The company had revenue of $25.71 million for the quarter, compared to analysts' expectations of $20.67 million. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. During the same quarter in the prior year, the company earned ($0.51) EPS. As a group, sell-side analysts predict that Personalis will post -1.41 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Personalis

Several large investors have recently added to or reduced their stakes in PSNL. Barclays PLC raised its holdings in shares of Personalis by 45.4% in the 3rd quarter. Barclays PLC now owns 65,468 shares of the company's stock valued at $352,000 after acquiring an additional 20,444 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Personalis by 20.0% in the 3rd quarter. Geode Capital Management LLC now owns 498,470 shares of the company's stock worth $2,683,000 after buying an additional 83,068 shares during the last quarter. Jane Street Group LLC increased its holdings in shares of Personalis by 154.3% in the 3rd quarter. Jane Street Group LLC now owns 164,281 shares of the company's stock worth $884,000 after buying an additional 99,671 shares during the last quarter. State Street Corp raised its position in shares of Personalis by 34.5% during the 3rd quarter. State Street Corp now owns 175,142 shares of the company's stock valued at $942,000 after buying an additional 44,900 shares in the last quarter. Finally, Centiva Capital LP bought a new stake in shares of Personalis during the 3rd quarter worth $380,000. Institutional investors own 61.91% of the company's stock.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.